Which IL17i to choose? Depends on the domain Dr. Armstrong: For the skin, the studies show brodalumab, ixekizumab and bimekizumab are superior to secukimumab for #psoriasis Dr. @AlexisOgdie noted we don't see much differences in these IL17i for the joints. #RNL2024 @rheumnow